Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

SOPHiA GENETICS and Karkinos Healthcare Collaborate to Propel Cancer Research in India

NextEdge Admin

24 Dec 2023

3 min 26 sec

SOPHiA GENETICS (Nasdaq: SOPH), a leading cloud-native software company specializing in data-driven medicine, has entered into a strategic partnership with Karkinos Healthcare, a purpose-driven cancer care technology network based in India. Karkinos Healthcare focuses on early detection, advanced diagnostics, and treatment delivery for common cancers through its Distributed Cancer Care Network across India.

The collaboration aims to leverage SOPHiA GENETICS’ SOPHiA DDM™ Platform to advance cancer testing and research for both blood cancers and solid tumors in underserved areas of low and middle-income countries. Karkinos Healthcare is committed to addressing accessibility and affordability gaps in cancer care through its ‘Community as a Cancer Centre’ initiative, aiming to serve one million patients annually. It offers comprehensive solutions across the entire oncology ecosystem, encompassing disease screening, diagnosis, surgery, chemotherapy, radiotherapy, and extensive patient navigation throughout the care continuum. Additionally, the company operates state-of-the-art research and development laboratories. This initiative addresses accessibility and affordability gaps in cancer care by employing a digitally curated hub-and-spoke model, extending its reach beyond comprehensive centers and ensuring a more widespread impact.

The SOPHiA DDM™ Platform is designed to compute a wide array of genomic variants and continuously improve machine learning algorithms to detect rare and challenging cases. Karkinos Healthcare will utilize this technology to expand its offerings, advance research, and enhance workflow for various blood cancers, including Myeloid cancer and Lymphoma. Additionally, the company will analyze solid tumors across different cancer types, such as ovarian, prostate, breast, pancreas, lung, colorectal, skin, and brain cancers.

Dr. Jurgi Camblong, CEO and Co-founder of SOPHiA GENETICS, emphasizes the shared goal of improving global health outcomes by increasing access to precision oncology. Dr. R Venkataramanan, Founder and CEO of Karkinos Healthcare, highlights the partnership’s potential to generate evidence and world-class research for faster and accurate cancer diagnosis and management, particularly benefiting underprivileged populations.

The SOPHiA DDM™ Platform’s tailored NGS-based workflows will streamline processes from sample to report, accelerating analysis and providing high-quality, reproducible data. This collaboration is poised to expedite clinical research studies and promote the adoption of precision medicine in cancer care.